よむ、つかう、まなぶ。
03【資料１】新型コロナワクチンの接種について (96 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_26922.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第33回 7／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
参考資料一覧（7/7）
諸外国における新型コロナワクチン追加接種の状況について
国際連合
WHO. 2021. Coronavirus Disease (COVID-19). https://extranet.who.int/pqweb/vaccines/covid-19-vaccines [Accessed July 21, 2022].
WHO. 2021. Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7 October 2021 https://cdn.who.int/media/docs/defaultsource/immunization/sage/2021/october/sage_oct2021_meetinghighlights.pdf?sfvrsn=3dcae610_11 [Accessed July 21, 2022].
UN News. 2021. WHO advisory group recommends extra COVID-19 vaccine dose for immunocompromised. https://news.un.org/en/story/2021/10/1102732 [Accessed July 21, 2022].
WHO. 2021. Interim statement on booster doses for COVID-19 vaccination. https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination [Accessed July 21,
2022].
WHO. 2021. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccinesSAGE_recommendation-BNT162b2-2021.1 [Accessed July 21, 2022].
WHO. 2022. Interim statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition
(TAG-CO-VAC), 08 March 2022. https://www.who.int/news/item/08-03-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-whotechnical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)-08-march-2022 [Accessed July 21, 2022]
EU
European Vaccination Information Portal. 2021. COVID-19 vaccines. https://vaccination-info.eu/en/covid-19/covid-19-vaccines [Accessed July 21, 2022].
European Medicines Agency. 2021. Comirnaty and Spikevax: EMA recommendations on extra doses boosters - European Medicines Agency. https://www.ema.europa.eu/en/news/comirnaty-spikevaxema-recommendations-extra-doses-boosters [Accessed July 21, 2022].
European Medicines Agency. 2021. Spikevax: EMA recommendation on booster - European Medicines Agency. https://www.ema.europa.eu/en/news/spikevax-ema-recommendation-booster [Accessed
July 21, 2022].
European Medicines Agency. 2021. EMA and ECDC recommendations on heterologous vaccination courses against COVID-19 - European Medicines Agency. https://www.ema.europa.eu/en/news/emaecdc-recommendations-heterologous-vaccination-courses-against-covid-19 [Accessed July 21, 2022].
European Medicines Agency. 2022. EMA recommends authorisation of booster doses of Comirnaty from 12 years of age. https://www.ema.europa.eu/en/news/ema-recommends-authorisation-boosterdoses-comirnaty-12-years-age [Accessed July 21, 2022].
EMA. 2022. COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. [online] Available at:
<https://www.ema.europa.eu/en/news/ema-recommends-authorisation-nuvaxovid-adolescents-aged-12-17> [Accessed 21 July 2022].
EMA. 2022. ECDC and EMA update recommendations on additional booster doses of mRNA COVID-19 vaccines - European Medicines Agency. [online] Available at:
<https://www.ema.europa.eu/en/news/ecdc-ema-update-recommendations-additional-booster-doses-mrna-covid-19-vaccines> [Accessed 21 July 2022].
96
96
諸外国における新型コロナワクチン追加接種の状況について
国際連合
WHO. 2021. Coronavirus Disease (COVID-19). https://extranet.who.int/pqweb/vaccines/covid-19-vaccines [Accessed July 21, 2022].
WHO. 2021. Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7 October 2021 https://cdn.who.int/media/docs/defaultsource/immunization/sage/2021/october/sage_oct2021_meetinghighlights.pdf?sfvrsn=3dcae610_11 [Accessed July 21, 2022].
UN News. 2021. WHO advisory group recommends extra COVID-19 vaccine dose for immunocompromised. https://news.un.org/en/story/2021/10/1102732 [Accessed July 21, 2022].
WHO. 2021. Interim statement on booster doses for COVID-19 vaccination. https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination [Accessed July 21,
2022].
WHO. 2021. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccinesSAGE_recommendation-BNT162b2-2021.1 [Accessed July 21, 2022].
WHO. 2022. Interim statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition
(TAG-CO-VAC), 08 March 2022. https://www.who.int/news/item/08-03-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-whotechnical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)-08-march-2022 [Accessed July 21, 2022]
EU
European Vaccination Information Portal. 2021. COVID-19 vaccines. https://vaccination-info.eu/en/covid-19/covid-19-vaccines [Accessed July 21, 2022].
European Medicines Agency. 2021. Comirnaty and Spikevax: EMA recommendations on extra doses boosters - European Medicines Agency. https://www.ema.europa.eu/en/news/comirnaty-spikevaxema-recommendations-extra-doses-boosters [Accessed July 21, 2022].
European Medicines Agency. 2021. Spikevax: EMA recommendation on booster - European Medicines Agency. https://www.ema.europa.eu/en/news/spikevax-ema-recommendation-booster [Accessed
July 21, 2022].
European Medicines Agency. 2021. EMA and ECDC recommendations on heterologous vaccination courses against COVID-19 - European Medicines Agency. https://www.ema.europa.eu/en/news/emaecdc-recommendations-heterologous-vaccination-courses-against-covid-19 [Accessed July 21, 2022].
European Medicines Agency. 2022. EMA recommends authorisation of booster doses of Comirnaty from 12 years of age. https://www.ema.europa.eu/en/news/ema-recommends-authorisation-boosterdoses-comirnaty-12-years-age [Accessed July 21, 2022].
EMA. 2022. COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. [online] Available at:
<https://www.ema.europa.eu/en/news/ema-recommends-authorisation-nuvaxovid-adolescents-aged-12-17> [Accessed 21 July 2022].
EMA. 2022. ECDC and EMA update recommendations on additional booster doses of mRNA COVID-19 vaccines - European Medicines Agency. [online] Available at:
<https://www.ema.europa.eu/en/news/ecdc-ema-update-recommendations-additional-booster-doses-mrna-covid-19-vaccines> [Accessed 21 July 2022].
96
96